Positive Early-Stage Clinical Data for Biogen Alzheimer’s Drug

Biogen Idec has announced plans to move their investigational Alzheimer’s drug into Phase III trials, after receiving promising early-stage clinical data. Douglas Williams, Biogen Idec’s R&D chief, noted that in the interim analysis of their Phase Ib clinical trial, aducanumab (also known as BIIB037) showed a significant reduction in the beta-amyloid protein in early-stage patients.

Continue Reading

MS drug hits Phase II targets

Biogen Idec and Abbott Laboratories have reported promising results in a Phase IIb trial of daclizumab, their once-monthly injectable treatment for multiple sclerosis. Top-line results from the dose-ranging SELECT trial in patients with the relapsing-remitting form of MS indicate that treatment with daclizumab at a dose of 150mg given by subcutaneous injection once every four

Continue Reading